Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GetGoal-L-C: Lixisenatide in T2DM Insufficiently Controlled With Basal Insulin
NCT01632163Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2012
- Primary completion
- May 2015
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 3 trial of lixisenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Oct 2012; status: completed.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01632163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632163.